1. Home
  2. HQI vs CRDF Comparison

HQI vs CRDF Comparison

Compare HQI & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HireQuest Inc. (DE)

HQI

HireQuest Inc. (DE)

HOLD

Current Price

$10.61

Market Cap

151.0M

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.59

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HQI
CRDF
Founded
2002
1999
Country
United States
United States
Employees
75000
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.0M
130.7M
IPO Year
2008
2012

Fundamental Metrics

Financial Performance
Metric
HQI
CRDF
Price
$10.61
$1.59
Analyst Decision
Buy
Strong Buy
Analyst Count
1
4
Target Price
$13.00
$9.63
AVG Volume (30 Days)
13.4K
555.2K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
2.33%
N/A
EPS Growth
73.08
27.37
EPS
0.45
N/A
Revenue
$30,640,000.00
$365,993.00
Revenue This Year
$0.08
N/A
Revenue Next Year
$6.06
N/A
P/E Ratio
$22.89
N/A
Revenue Growth
N/A
49.61
52 Week Low
$7.38
$1.48
52 Week High
$12.48
$4.56

Technical Indicators

Market Signals
Indicator
HQI
CRDF
Relative Strength Index (RSI) 52.22 36.69
Support Level $10.38 $1.51
Resistance Level $10.66 $1.68
Average True Range (ATR) 0.57 0.08
MACD 0.07 -0.01
Stochastic Oscillator 70.55 12.12

Price Performance

Historical Comparison
HQI
CRDF

About HQI HireQuest Inc. (DE)

HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: